THE EFFECT OF LONG-TERM MELATONIN SUPPLEMENTATION ON PSYCHOSOMATIC DISORDERS IN POSTMENOPAUSAL WOMEN

被引:17
|
作者
Chojnacki, C. [1 ]
Kaczka, A. [1 ]
Gasiorowska, A. [2 ]
Fichna, J. [3 ]
Chojnacki, J. [1 ]
Brzozowski, T. [4 ]
机构
[1] Med Univ, Dept Clin Nutr & Gastroenterol Diagnost, 1 J Haller Sq, PL-90647 Lodz, Poland
[2] Med Univ, Dept Gastroenterol, Lodz, Poland
[3] Med Univ, Dept Biochem, Lodz, Poland
[4] Jagiellonian Univ, Fac Med, Dept Physiol, Med Coll, Krakow, Poland
来源
关键词
melatonin; estradiol; follicle-stimulating hormone; psychosomatic disorders; 6-sulfatoxymelatonin; menopause; climacteric disorders; URINARY 6-SULFATOXYMELATONIN EXCRETION; HORMONE-THERAPY; NONALCOHOLIC STEATOHEPATITIS; INTRAVENOUS MELATONIN; LIVER-ENZYMES; MENOPAUSAL; SLEEP; PHARMACOKINETICS; SECRETION; SYMPTOMS;
D O I
10.26402/jpp.2018.2.15
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Different psychosomatic disorders are observed in postmenopausal women. The decrease of estrogen production is believed to be the main cause of their severity. It is nowadays evident that the decreased melatonin release in women at this age who suffer from postmenopausal disorders might also contribute to the severity of the symptoms. The aim of the study was to evaluate the effect of melatonin supplementation on female hormones release and the alteration in climacteric symptoms. The study included 60 postmenopausal women, aged 51 - 64 years, who were randomly allotted into two equal groups. Group I was recommended placebo (2 x 1 tablet) and Group II - melatonin (3 mg in the morning and 5 mg at bedtime) for 12 months. Serum levels of 17 beta-estradiol, follicle-stimulating hormone (FSH), melatonin and urinary 6-sulfatoxymelatonin (aMT6s) excretion as well as Kupperman Index (KI) and body mass index (BMI) were determined before the start and at 12 months after placebo or melatonin administration. In Group I only the value of KI slightly decreased (28.4 +/- 2.9 versus 25.6 +/- 3.8 points, P = 0,0619). In Group II - KI decreased from 29.1 +/- 2.9 to 19.7 +/- 3.1 points (P < 0.001) and BMI from 30.9 +/- 2.9 to 28.1 +/- 2.3 kg/m(2) (P < 0.05). Melatonin supplementation failed to change significantly the serum concentration of female reproductive hormones 17 beta-estradiol and FSH. We conclude that melatonin supplementation therapy exerts a positive effect on psychosomatic symptoms in postmenopausal women and can be recommended as the useful adjuvant therapeutic option in treatment of these disorders.
引用
收藏
页码:297 / 304
页数:8
相关论文
共 50 条
  • [31] Long-term aircraft noise exposure and risk of hypertension in postmenopausal women
    Nguyen, Daniel D.
    Whitsel, Eric A.
    Wellenius, Gregory A.
    Levy, Jonathan, I
    Leibler, Jessica H.
    Grady, Stephanie T.
    Stewart, James D.
    Fox, Matthew P.
    Collins, Jason M.
    Eliot, Melissa N.
    Malwitz, Andrew
    Manson, JoAnn E.
    Peters, Junenette L.
    ENVIRONMENTAL RESEARCH, 2023, 218
  • [32] Cochrane corner: long-term hormone therapy for perimenopausal and postmenopausal women
    Marjoribanks, Jane
    Farquhar, Cindy Margaret
    Roberts, Helen
    Lethaby, Anne
    HEART, 2018, 104 (02) : 93 - 95
  • [33] The long-term effects of tibolone on libido in surgically postmenopausal women.
    Tutuncu, L
    Ergur, AR
    Mungen, E
    Muheu, M
    Yergok, YZ
    FERTILITY AND STERILITY, 2004, 82 : S78 - S78
  • [34] Short-termand long-term effects of tibolone in postmenopausal women
    Formoso, Giulio
    Perrone, Enrica
    Maltoni, Susanna
    Balduzzi, Sara
    Wilkinson, Jack
    Basevi, Vittorio
    Marata, Anna Maria
    Magrini, Nicola
    D'Amico, Roberto
    Bassi, Chiara
    Maestri, Emilio
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2016, (10):
  • [35] Long-Term Outcome of Postmenopausal Women With Proliferative Endometrium on Endometrial Sampling
    Rotenberg, Ohad
    Doulaveris, Georgios
    Fridman, Dmitry
    Renz, Malte
    Kaplan, Julie
    Xie, Xianhong
    Goldberg, Gary L.
    Dar, Pe'er
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2020, 75 (11) : 672 - 673
  • [36] THERE IS NO HYPERMINERALIZATION AMONG POSTMENOPAUSAL WOMEN RECEIVING LONG-TERM ORAL BISPHOSPHONATES
    Bala, Y.
    Chapurlat, R.
    Delmas, P. D.
    Boivin, G.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 68 - 68
  • [37] Hemostatic Markers and Long-Term Risk of Intracerebral Hemorrhage in Postmenopausal Women
    Lee, Ju-Mi
    Siddique, Juned
    Kim, Hyeon Chang
    Green, David
    Van Horn, Linda
    Allison, Matthew
    Wassertheil-Smoller, Sylvia
    Greenland, Philip
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2016, 25 (07): : 1639 - 1643
  • [38] Is long-term bisphosphonate therapy associated with benefits to the periodontium in postmenopausal women?
    Palomo, Leena
    Buencamino-Francisco, Maria Clarinda A.
    Carey, John J.
    Sivanandy, Mala
    Thacker, Holly
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2011, 18 (02): : 164 - 170
  • [39] EFFECTS OF LONG-TERM ADMINISTRATION OF ESTROGENS ON SERUM LIPIDS OF POSTMENOPAUSAL WOMEN
    ROBINSON, RW
    HIGANO, N
    COHEN, WD
    NEW ENGLAND JOURNAL OF MEDICINE, 1960, 263 (17): : 828 - 831
  • [40] Long-term outcome of postmenopausal women with proliferative endometrium on endometrial sampling
    Rotenberg, Ohad
    Doulaveris, Georgios
    Fridman, Dmitry
    Renz, Malte
    Kaplan, Julie
    Xie, Xianhong
    Goldberg, Gary L.
    Dar, Pe'er
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2020, 223 (06) : 896.e1 - 896.e7